Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: The potential role of inflammation

Europace

Volumn 11, Issue 2, 2009, Pages 158-163

  Letsas, Konstantinos P ^a   Weber, Reinhold ^a   Bürkle, Gerd ^a   Mihas, Constantinos C ^a   Minners, Jan ^a   Kalusche, Dietrich ^a   Arentz, Thomas ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

Ablation; Atrial fibrillation; Inflammation; Obesity; Recurrence

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FLECAINIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPAFENONE; QUINIDINE; SOTALOL; SPIRONOLACTONE; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BODY MASS; CATHETER ABLATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ELECTROSURGERY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART SIZE; HUMAN; HYPERTENSION; INFLAMMATION; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PULMONARY VEIN; PULMONARY VEIN ISOLATION; RECURRENT DISEASE; UNIVARIATE ANALYSIS;

ATRIAL FIBRILLATION; C-REACTIVE PROTEIN; CATHETER ABLATION; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HEART ATRIA; HEART VENTRICLES; HUMANS; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY VEINS; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 59449093018     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun309     Document Type: Article

References (25)

1. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49.
2. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
3. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007;50:2021-8.
4. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007;49:1642-8.
5. Lamm G, Auer J, Weber T, Berent R, Ng C, Eber B. Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery. J Cardiothorac Vasc Anesth 2006;20:51-6.
6. Abdelhadi RH, Gurm HS, Van Wagoner DR, Chung MK. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol 2004;93:1176-8.
7. Korantzopoulos P, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int J Clin Pract 2005;59:881-5.
8. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jönsson A, Säfström K et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008;10:848-53.
9. Frustaci A, Chimente C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4.
10. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2007;9:335-79.
11. O'Neill MD, Jaïs P, Hocini M, Sacher F, Klein GJ, Clémenty J et al. Catheter ablation for atrial fibrillation. Circulation 2007;116:1515-23.
12. Arentz T, Weber R, Bürkle G, Herrera C, Blum T, Stockinger J et al. Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation? Results from a prospective randomized study. Circulation 2007;115:3057-63.
13. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
14. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-54.
15. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92.
16. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005;95:764-7.
17. Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 2005;20:45-9.
18. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-7.
19. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 2005;118:489-95.
20. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005;112:3247-55.
21. Mainigi SK, Sauer WH, Cooper JM, Dixit S, Gerstenfeld EP, Callans DJ et al. Incidence and predictors of very late recurrence of atrial fibrillation after ablation. J Cardiovasc Electrophysiol 2007;18:69-74.
22. Berruezo A, Tamborero D, Mont L, Benito B, Tolosana JM, Sitges M et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 2007;28:836- 41.
23. Sauer WH, McKernan ML, Lin D, Gerstenfeld EP, Callans DJ, Marchlinski FE. Clinical predictors and outcomes associated with acute return of pulmonary vein conduction during pulmonary vein isolation for treatment of atrial fibrillation. Heart Rhythm 2006;3:1024-8.
24. Al Chekakie MO, Akar JG, Wang F, Al Muradi H, Wu J, Santucci P et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007;18:942-6.
25. Richter B, Derntl M, Marx M, Lercher P, Gössinger HD. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007;153:113-9.